Inositol trisphosphate-dependent and -independent Ca2+ mobilization pathways at the vacuolar membrane of Candida albicans.
Vacuolar membrane vesicles were isolated from Candida albicans protoplasts, and marker enzyme assays were employed to identify the membranes as vacuolar in origin. The mechanisms of Ca2+ uptake and Ca2+ release at the vacuolar membrane were investigated. Ca2+ accumulation by vacuolar membrane vesicles can be generated via H+/Ca2+ antiport. The inside-acid pH is in turn generated by a vacuolar-type H(+)-ATPase, as demonstrated by the sensitivity of Ca2+ uptake to ionophores and the vacuolar H(+)-ATPase inhibitor bafilomycin A1. Vacuolar membrane vesicles exhibit two Ca2+ release pathways: one induced by inositol 1,4,5-trisphosphate (InsP3) and the other by inside-positive voltage. These two pathways are distinct with respect to the amount of Ca2+ released, the nature of response to successive stimuli, and their respective pharmacological profiles. The InsP3-gated pathway exhibits a K0.5 for InsP3 of 2.4 microM but is not activated by inositol 4,5-bisphosphate or inositol 1,3,4,5-tetrakisphosphate at concentrations up to 50 microM. Ca2+ release by InsP3 is blocked partially by low molecular weight heparin. Ca2+ released by the voltage-sensitive pathway occurs at membrane potentials estimated to be over a physiological range from 0 to 80 mV. The voltage-sensitive Ca2+ release pathway can be blocked by lanthanide ions and organic channel blockers such as ruthenium red and verapamil. Furthermore, the voltage-sensitive Ca2+ release pathway exhibits Ca(2+)-induced Ca2+ release. These findings are discussed in relation to the mechanism of Ca(2+)-mediated cellular signaling in C. albicans and other fungi.
Calvert
C M
CM
Biology Department, University of York, United Kingdom.
Sanders
D
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002176:Candida albicans / Q000378:metabolism*; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D015544:Inositol 1,4,5-Trisphosphate / Q000494:pharmacology*; D007295:Inositol Phosphates / Q000494:pharmacology; D007425:Intracellular Membranes / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D018942:Macrolides; D008345:Manganese / Q000494:pharmacology; D009861:Onium Compounds / Q000494:pharmacology; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013104:Spheroplasts / Q000378:metabolism; D014320:Triphenylmethyl Compounds / Q000494:pharmacology; D014617:Vacuoles / Q000187:drug effects / Q000378:metabolism*; D014700:Verapamil / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D007295:Inositol Phosphates; D018942:Macrolides; D009861:Onium Compounds; D014320:Triphenylmethyl Compounds; C011561:triphenylmethylphosphonium; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; D008345:Manganese; D004533:Egtazic Acid; D015544:Inositol 1,4,5-Trisphosphate; C040929:bafilomycin A1; D006493:Heparin; D014700:Verapamil; D006180:Proton-Translocating ATPases; D002118:Calcium